抗菌漱口水预防淋病(OMEGA):随机双盲平行组多中心试验
OMEGA试验在澳大利亚四个城市门诊纳入MSM,比较Listerine与Biotène漱口水预防口咽淋病的效果。
要点
- Listerine漱口水未较Biotène降低MSM口咽淋病发病率。
核心结论
- 与Biotène相比,Listerine未降低MSM口咽淋病的发病率。
- 既往研究提示漱口水可能降低口咽淋病传染性,需进一步研究其抑制淋球菌作用。
研究设计与样本
- 多中心、平行组、双盲随机对照试验,在澳大利亚三个城市性健康诊所和一个全科诊所开展。
- 纳入MSM:过去30天内NAAT确诊口咽淋病或年龄16-24岁。
- 随机分配接受Listerine(干预)或Biotène(对照),按1:1比例、区组大小4。
- 参与者每日至少一次用20 mL漱口水含漱60秒,持续12周。
- 主要结局:12周内口咽拭子或唾液NAAT阳性比例及第12周累积发病率。
主要发现
- 筛查786名MSM,排除256名;随机分配Biotène组264人、Listerine组266人。
- 分析人群:Biotène组227人(86%),Listerine组219人(82%)。
关键数值与推荐
- 主要结局采用改良意向性分析,纳入至少提供一次随访标本的男性。
- 口咽淋病定义为口咽拭子或唾液样本NAAT阳性。
临床怎么用
- 不推荐使用Listerine漱口水作为MSM口咽淋病的预防措施。
- 漱口水对淋球菌的抑制效果及传播阻断作用需进一步研究。
局限性
- 原文未报告局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To address the increasing incidence of gonorrhoea and antimicrobial resistance, we compared the efficacy of Listerine and Biotène mouthwashes for preventing gonorrhoea among men who have sex with men (MSM). METHODS: The OMEGA trial was a multicentre, parallel-group, double-blind randomised controlled trial among MSM, done at three urban sexual health clinics and one general practice clinic in Australia. Men were eligible if they were diagnosed with oropharyngeal gonorrhoea by nucleic acid amplification test (NAAT) in the previous 30 days or were aged 16-24 years. They were randomly assigned to receive Listerine (intervention) or Biotène (control) via a computer-generated sequence (1:1 ratio, block size of four). Participants, clinicians, data collectors, data analysts, and outcome adjudicators were masked to the interventions after assignment. Participants were instructed to rinse and gargle with 20 mL of mouthwash for 60 s at least once daily for 12 weeks. Oropharyngeal swabs were collected by research nurses every 6 weeks, and participants provided saliva samples every 3 weeks, to be tested for Neisseria gonorrhoeae with NAAT and quantitative PCR. The primary outcome was proportion of MSM diagnosed with oropharyngeal N gonorrhoeae infection at any point over the 12-week period, defined as a positive result for either oropharyngeal swabs or saliva samples by NAAT, and the cumulative incidence of oropharyngeal gonorrhoea at the week 12 visit. A modified intention-to-treat analysis for the primary outcome was done that included men who provided at least one follow-up specimen over the 12-week study period. The trial was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12616000247471). FINDINGS: Between March 30, 2016, and Oct 26, 2018, 786 MSM were screened and 256 were excluded. 264 MSM were randomly assigned to the Biotène group and 266 to the Listerine group. The analysis population included 227 (86%) men in the Biotène group and 219 (82%) in the Listerine group. Oropharyngeal gonorrhoea was detected in ten (4%) of 227 of MSM in the Biotène group and in 15 (7%) of 219 in the Listerine group (adjusted risk difference 2·5%, 95% CI -1·8 to 6·8). The cumulative incidence of oropharyngeal gonorrhoea at the week 12 visit did not differ between the two mouthwash groups (adjusted risk difference 3·1%, 95% CI -1·4 to 7·7). INTERPRETATION: Listerine did not reduce the incidence of oropharyngeal gonorrhoea compared with Biotène. However, previous research suggests that mouthwash might reduce the infectivity of oropharyngeal gonorrhoea; therefore, further studies of mouthwash examining its inhibitory effect on N gonorrhoeae are warranted to determine if it has a potential role for the prevention of transmission. FUNDING: Australian National Health and Medical Research Council.
引用
- Chow EPF, Williamson DA, Hocking JS, et al. Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. Lancet Infect Dis. 2021. PMID: 33676595. doi:10.1016/S1473-3099(20)30704-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。